InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia
NCT05961059 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 85
Last updated 2024-11-07
Summary
The goal of this clinical trial is to test a new Shigella vaccine (InvaplexAR-DETOX) in combination with a new adjuvant (dmLT) in healthy participants. The main questions it aims to answer are:
* Is the new Shigella vaccine (with and without the new adjuvant) safe and well tolerated?
* How wel does the new Shigella vaccine stimulate the immune system in combination with the new adjuvant, and without the new adjuvant?
Participants will receive three vaccinations at 28-day intervals. Researchers will compare the results of participants vaccinated with the vaccine in combination with the adjuvant to the results of participants vaccinated with the vaccine only and to the results of participants vaccinated with a placebo (fake vaccine).
Conditions
- Shigellosis
- Bacillary Dysentery
Interventions
- BIOLOGICAL
-
2.5 μg InvaplexAR-Detox
2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
- BIOLOGICAL
-
10 μg InvaplexAR-Detox
10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
- BIOLOGICAL
-
0.1 μg of dmLT
0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
- BIOLOGICAL
-
Placebo vaccination with commercially available saline solution.
Sponsors & Collaborators
-
Centre for Infectious Disease Research in Zambia
collaborator OTHER -
PATH
collaborator OTHER -
Walter Reed Army Institute of Research (WRAIR)
collaborator FED -
Göteborg University
collaborator OTHER -
European Vaccine Initiative
collaborator OTHER -
European and Developing Countries Clinical Trials Partnership (EDCTP)
collaborator OTHER_GOV -
Leiden University Medical Center
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-10-10
- Primary Completion
- 2025-05-31
- Completion
- 2025-05-31
- FDA Drug
- Yes
Countries
- Netherlands
Study Locations
More Related Trials
-
Zinc Supplementation in Shigella Patients
NCT00321126 ·Status: COMPLETED ·Phase: PHASE3
-
Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection
NCT02005653 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
NCT02864433 ·Status: COMPLETED
-
Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
NCT02839161 ·Status: COMPLETED ·Phase: PHASE1
-
Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance
NCT04853186 ·Status: RECRUITING
-
Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition
NCT01395381 ·Status: WITHDRAWN ·Phase: NA
-
Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants
NCT01571856 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy
NCT01440608 ·Status: COMPLETED ·Phase: NA
-
Arachidonic Acid Treatment Against Schistosomiasis Infection in Children
NCT02144389 ·Status: COMPLETED ·Phase: NA
-
Study of Nitazoxanide in the Treatment of Amebiasis in Children
NCT00366730 ·Status: COMPLETED ·Phase: PHASE3
-
Repeated Controlled Human Hookworm Infection
NCT03257072 ·Status: COMPLETED ·Phase: NA
-
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
NCT03373669 ·Status: COMPLETED ·Phase: PHASE4
-
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)
NCT02868385 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
NCT04913610 ·Status: TERMINATED ·Phase: PHASE2
-
Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition
NCT01000298 ·Status: COMPLETED ·Phase: NA
-
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
NCT01019083 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant
NCT01385189 ·Status: COMPLETED ·Phase: PHASE1
-
Triple Combinations Against Hookworm Infections in Lao
NCT03278431 ·Status: COMPLETED ·Phase: PHASE4
-
Efficiency and Safety of Zinc Sulphate to Reduce the Duration of Acute Diarrheal Disease Between 6 and 59 Months of Age
NCT04061538 ·Status: COMPLETED ·Phase: NA
-
Praziquantel in Children Under Age 4
NCT03640377 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of iOWH032 in Dehydrating Cholera
NCT02111304 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)
NCT06128447 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora
NCT01192802 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Pediculosis (Head Lice) in Senegal
NCT03578679 ·Status: COMPLETED ·Phase: NA
-
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
NCT03664063 ·Status: COMPLETED ·Phase: PHASE2